According to International Agency for Research on Cancer, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 globally. In recent times, cell line development and its applications are considered potential tools in oncology research. Cell lines are projected to be used for the development of new treatment pathways for various diseases including cancer and neurological diseases. According to the latest research by Future Market Insights (FMI), the global cell line development market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end. The report on cell line development market further projects significant growth potential with CAGR at 7.2% through 2028.
The rapid increase in the prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.
To remain 'ahead' of your competitors, request for a sample>>> https://www.futuremarketinsights.com/reports/sample/rep-gb-7566
In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn.
In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST). Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.
The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market. Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.
Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.
Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market. Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection.
Get Access to Research Methodology Prepared by Experts>>> https://www.futuremarketinsights.com/ask-question/rep-gb-7566
For example, Gaucher's disease, which is a genetic disorder characterized by lack of B-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body.
North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market. The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/7566
FMI's report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.
More from Healthcare, Pharmaceuticals and Medical devices:
- Prefilled Formalin Vials Market Segmentation By Product Type – <10 mL, 10 – 20 mL, 20 – 40 mL, 40 – 60 mL, 60 – 90 mL, 90 – 500 mL, and 500 mL – 1 Litre
- Opioid Withdrawal Management Market Segmented By Drugs – Opioid Agonists, Opioid Antagonists, Antidepressants; By Material of construction; By Application Area, By Distribution Channels
- Acoustic Puncture Assist Devices Market Segmented By Drug Type; By Route of Administration, By Distribution Channel; End User: Hospitals, Ambulatory Surgical Centres, Specialty Clinics
The cell line development market is a for all time built up cell culture that will multiply uncertainly given suitable crisp medium and space and are frequently utilized instead of essential cells to consider natural procedures.
Cell line development alludes to the way toward creating stable cell lines for the utilization in various significant applications including biologics (for example recombinant protein and monoclonal neutralizer) generation, tranquilize screening, and quality practical investigations.
We have included all the segment of this market in our market research report.
Cell Line Development Market Research Report: Information By Type (Primary cell, Hybridoma Cell Line, Continuous Cell Line, Recombinant Cell Line), By Product (Equipment, Media and Reagents), Scource Mammalian cells, Non Mammalian cells), Application (Drug Discovery, Bioproduction, Tissue Engineering, Others), Region (North America, Europe, Asia-Pacific, Rest of the World) Forecast till 2027Market HighlightsAccording to MRFR analysis, the global cell line development market is expected to register a CAGR of 12.5 from 2021 to 2027 and hold a value of USD 10,700 million by 2027.The global cell line development market is driven by the increasing R in the pharmaceutical and biopharmaceutical industry, focusing on cell line development.
The developing economiesare also contributing to the increasing R activities.
For instance,in October 2019, ATCC launched a new authentication service that helps researchers easily confirm mouse cell lines’ identity.
The service demonstrates ATCC’s continued leadership in developing global biological standards.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/9131 Regional AnalysisBased on region, North America is anticipated to dominate the global cell line development market in the year 20120, owing to the factors such as the growing number of application of cell line development in new treatment pathway for various diseases such as cancer and other neurological disease, well-established healthcare infrastructure, government support to accelerate research in biotechnology and biopharmaceutical industry, and presence of key players in this region involved in product launch, expansion, acquisition & strategic collaborations.
The recombinant cell line consists of recombinant DNA.
The advances in rDNA technology offers enzymes, synthetic hormones immunobiological and anti-cancer agents that is contributing to the market growth of this segment.
